US$2.75: That's What Analysts Think IRIDEX Corporation (NASDAQ:IRIX) Is Worth After Its Latest Results
IRIDEX Corporation (NASDAQ:IRIX) missed earnings expectations, with revenues of US$13m and a loss of US$0.07 per share. Analysts reduced the price target by 8.3% to US$2.75, citing increased loss expectations for 2026. Despite a forecasted 3.7% annual revenue growth, it lags behind the industry's 7.6% growth estimate.
How this was made
The 30-second read
Why it matters
The earnings miss and widened loss forecast drive a negative sentiment, likely pressuring the stock toward the revised $2.75 target.
Market read
Company‑specific earnings miss with modest scale; limited broader market impact.
What to watch
Potential pipeline products or contract wins not disclosed in this brief could offset short‑term loss.
Background
IRIDEX is a small‑cap ophthalmic device maker listed on NASDAQ. The article summarizes its latest quarterly earnings and analyst price‑target adjustment.
Ticker impact
IRIDEX missed earnings, reporting a loss of $0.07 per share and a revenue of $13M, causing the consensus price target to fall to $2.75.
Potential further decline toward the new $2.75 target.
The loss per share increased while revenue remained flat, prompting analysts to lower the price target.
Market effects
Highlights weakness in the niche ophthalmic device sector, may pressure peers.
Limited to US micro‑cap market; no broader regional effect.
Low global relevance; primarily a company‑specific event.
Counterpoint
If the loss is a one‑time charge, the stock could rebound on a future turnaround.
Key entities
- companyIRIDEX Corporation
NASDAQ‑listed ophthalmic device manufacturer.
